Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.Combating Opioid-Induced Constipation: New and Emerging TherapiesBevenopran
See also Alvimopan Axelopran Eluxadoline Methylnaltrexone Naldemedine Naloxegol
References